StreetInsider.com News Articles

Design Therapeutics (DSGN) Reiterated at Overweight by Cantor Fitzgerald

Wed, 01 Jul 2026 06:59:45 -0400

Cantor Fitzgerald analyst Yanni Souroutzidis reiterated an Overweight rating on Design Therapeutics Inc (NASDAQ: DSGN).

The analyst commented, "USS is the more stable endpoint, and we now place more limited weight on frataxin given that approval will ultimately hinge on function. USS is the more stable endpoint, and the signal here looks real: against the EPI study’s placebo benchmark, the 1mpk USS result sits far out in the tail (~0.1% of random 4-patient draws) and the dose response is clean and consistent across cohorts. Rummey’s placebo-response work shows mFARS can be inflated by frequent testing and older baselines – and RESTORE-FA’s

Design Therapeutics begins patient dosing in Phase 1 DT-818 trial

Tue, 30 Jun 2026 08:00:48 -0400

Design Therapeutics, Inc. (Nasdaq: DSGN) announced the initiation of patient dosing in a Phase 1 multiple ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1), according to a company press release.

DT-818 is a GeneTAC small molecule designed to selectively reduce transcription of the mutant DMPK allele, which the company says addresses the underlying genetic cause of DM1. The disease is a progressive neuromuscular condition affecting skeletal muscle, heart, brain and other organs, estimated to affect more than 70,000 people in the United States.

The Phase 1 trial is an open-label study designed to evaluate the safety,

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

Tue, 30 Jun 2026 08:00:00 -0400

GeneTAC^® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1

CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1). DT-818 is a GeneTAC^® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1.

"Initiation of patient

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

Tue, 30 Jun 2026 08:00:00 -0400

GeneTAC^® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1

"Initiation of patient

Form 4 Design Therapeutics, For: Jun 09 Filed by: George Simeon

Thu, 11 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260611/26636415.html

Form 4 Design Therapeutics, For: Jun 09 Filed by: George Simeon

Thu, 11 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260611/26636415.html

Form 4 Design Therapeutics, For: Jun 09 Filed by: LAPPE RODNEY W